Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Implementation and Evaluation of a Complex Intervention to Reduce Avoidable Transitions Between Nursing Home and Hospital

NCT07359521 · tracked via the Priya Life Science Belgium tracker
Phase
Not applicable
Started
2026-06-01
Last updated
2026-08-10

Condition(s) studied

Potentially Avoidable Hospitalisations

Investigational drug(s) / intervention(s)

RATHER-NH Toolkit

RATHER-NH Toolkit: A) Stop and Watch Early Warning Tool B) Decision trees C) General Practitioner communication tool

Study summary

Hospital admissions can have a negative impact on the physical and emotional health of nursing home residents. Although evidence-based interventions have been developed to reduce hospitalisations, the evidence regarding their effectiveness is inconclusive and challenges have been reported in implementing these interventions within the nursing home context. Hence, this study aimed to implement and evaluate a complex intervention to reduce avoidable transitions between nursing home and hospital (RATHER-NH).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria for nursing homes: * A capacity of at least 60 beds * Active engagement for the study from nursing home management, head nurses and the coordinating \& advisory physician, meaning: 1. The nursing home manager, head nurses and the coordinating \& advisory physician agree that the implementation of the RATHER-NH intervention is a priority for their facility. 2. The nursing home manager agrees to provide time for the nursing home staff members to participate in activities related to the implementation of RATHER-NH such as attending information sessions, training workshops, and feedback moments. 3. The nursing home manager is willing to allocate time to at least two nursing home staff members (each approximately 0.1 FTE for the study duration) to act as local project champions and to at least four other staff members (type of staff to be decided with the nursing home manager) to form a local action team to support the implementation and evaluation of RATHER-NH. Exclusion criteria for nursing homes: * Already participated in another project designed to reduce potentially avoidable hospitalisations. * Already taking part in another major quality improvement initiative or study. * A large reorganisation or change in staff is taking place or is planned during the study period.

Primary outcome measure(s)

  • Outcomes on healthcare use per 100 person-months — Retrospective baseline measurement of 3 months, during the intervention (period of 9 months) untill 3 months post-intervention for the post-interventions measurement.
    Rate of hospitalisations per 100 person-months, rate of out-of-hours GP contacts per 100 person-months, rate of emergency department visits (without hospitalisation) per 100 person-months.
  • Outcomes on healthcare use per hospitalisation — Retrospective baseline measurement of 3 months, during the intervention (period of 9 months) untill 3 months post-intervention for the post-interventions measurement.
    Length of hospital stay, cause of hospitalisation, hospitalisation in the last month of life (in case of death) and place of death

Trial sites (6)

FacilityCityRegionStatus
WZC De Cocon Dendermonde Belgium
WZC Sint-Elisabeth Eeklo Belgium
WZC Domino Ghent Belgium
WZC Annuntiaten Heverlee Belgium
WZC Ter Moere Lokeren Belgium
WZC Martinas Merchtem Belgium
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07359521 on ClinicalTrials.gov ↗ ← All trials in Belgium